Pennsylvania is currently home to 3459 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: CCT Research, Hatboro, Pennsylvania
Conditions: Type 2 Diabetes
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/22/2024
Locations: Akero Clinical Study Site, Philadelphia, Pennsylvania
Conditions: NASH/MASH, NAFLD/MASLD
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/22/2024
Locations: Abington Neurological Associates Site Number : 8401065, Abington, Pennsylvania
Conditions: Multiple Sclerosis
Register for Updates
Helix Research Network
NCT06057181
Recruiting
The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clinical care.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: St. Luke's University Health Network (DNAanswers), Bethlehem, Pennsylvania
Conditions: Genetic Predisposition to Disease, Genetics Disease
Register for Updates
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
NCT06015308
Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in ad... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Vial Health @DermDox Dermatology Site Number : 8401031, Camp Hill, Pennsylvania
Conditions: Dermatitis Atopic
Register for Updates
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
NCT05941442
Recruiting
The purpose of this trial is to measure the efficacy, safety, and tolerability of darigabat (25 milligrams [mg] twice daily [BID]) compared with placebo in participants with panic disorder.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2024
Locations: West Chester, Pennsylvania, West Chester, Pennsylvania
Conditions: Panic Disorder
Register for Updates
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464
Recruiting
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to < 12 years), and a Phase 2 cohort.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/22/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Register for Updates
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
NCT05775848
Recruiting
This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.
Gender:
All
Ages:
Between 12 years and 60 years
Trial Updated:
04/22/2024
Locations: Penn State, Hershey, Pennsylvania
Conditions: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Register for Updates
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229
Recruiting
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Research Site, Pittsburgh, Pennsylvania
Conditions: Gastric Cancer
Register for Updates
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
NCT05624268
Recruiting
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Global Medical Institutes, LLC, Scranton Medical Institute, Moosic, Pennsylvania
Conditions: Treatment Resistant Depression
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 4
NCT05617014
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
04/22/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Register for Updates
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT05568680
Recruiting
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
Register for Updates